politics

Eli Lilly Acquires Psychedelics Company AtaiBeckley for $2.8 Billion

16 Temmuz 2026CNBC

Eli Lilly is set to acquire AtaiBeckley for $2.8 billion, marking a significant move into the psychedelics market. This acquisition will provide Lilly with access to experimental treatments utilizing DMT and MDMA, which have been gaining attention for their potential therapeutic benefits.
As interest in psychedelics grows, this deal positions Lilly to capitalize on emerging trends in mental health treatment.
Psychedelics have been under scrutiny for decades, but recent studies have highlighted their potential in treating conditions such as depression and PTSD. As the stigma surrounding these substances diminishes, pharmaceutical companies are increasingly looking to invest in this burgeoning field.
The acquisition of AtaiBeckley by Eli Lilly reflects a broader trend in the pharmaceutical industry towards exploring psychedelics as viable treatment options. With increasing research supporting the efficacy of substances like DMT and MDMA, Lilly's investment could not only enhance its product pipeline but also sig…

NewsAI özeti

This article is for informational purposes only and does not constitute financial advice.